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This study was designed to examine the antioxidant defense by ethanolic extract of Embelia ribes on streptozotocin-(40mg/kg,
intravenously, single-injection) induced diabetes in Wistar rats. Forty days of oral feeding the extract (100mg/kg and 200mg/kg)
to diabetic rats resulted in signiﬁcant (P<. 01) decrease in blood glucose, blood glycosylated haemoglobin, serum lactate dehydro-
genase, creatine kinase, and increase in blood glutathione levels as compared to pathogenic diabetic rats. Further, the extract also
signiﬁcantly (P<. 01) decreased the pancreatic thiobarbituric acid-reactive substances (TBARS) levels and signiﬁcantly (P<. 01)
increased the superoxide dismutase, catalase, and glutathione levels as compared to above levels in pancreatic tissue of pathogenic
diabetic rats. The islets were shrunken in diabetic rats in comparison to normal rats. In the drug-treated diabetic rats, there was
expansion of islets. The results of test drug were comparable to gliclazide (25mg/kg, daily), a standard antihyperglycemic agent.
The study concludes that Embelia ribes enhances the antioxidant defense against reactive oxygen species produced under hyper-
glycemic condition and this protects β-cells against loss, and exhibit antidiabetic property.
Copyright © 2007 Uma Bhandari et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Diabetes mellitus, a global public health problem, is now
emerging as a pandemic and by the year 2025, three quar-
ters of the world’s 300 million adults with diabetes will be in
nonindustrialized countries, and almost a third in India and
China alone [1].
Increased free radical generation and oxidative stress are
hypothesized to play an important role in pathogenesis of
diabetes and its late complications [2]. Possible sources of
oxidative stress and damage to proteins in diabetes include
free radicals generated by auto-oxidation reactions of sug-
ars and sugars adducts to proteins and by auto-oxidation of
unsaturated lipids in plasma and membrane proteins. The
oxidative stress may be ampliﬁed by a continuing cycle of
metabolic stress, tissue damage, and cell death, leading to in-
creased free radical production and compromised free radi-
cal inhibitory and scavenger systems, which further exacer-
bate the oxidative stress [3]. Indeed, there is widespread ac-
ceptance of possible role of reactive oxygen species (ROS)
generated as a result of hyperglycaemia in causing many of
the secondary complications of diabetes such as nephropa-
thy, retinopathy, neuropathy [4], and cardiomyopathy [5].
Glycation reaction in diabetes occurs in various tissues in-
cluding β-cells [6, 7]. The activity of antioxidant enzymes
such as superoxide dismutase, catalase, and glutathione per-
oxidase, which is low in islet cells when compared to other
tissues, becomes further worsened under diabetic conditions
[8]. Further, the presence of higher glucose or glycated pro-
tein concentration enhances lipid peroxidation [9], and fur-
thermorelipidperoxidesmayincreasetheextentofadvanced
glycation end products [10].
Thepharmacotherapyofdiabeteshasrecentlyundergone
unprecedented expansion. However, the challenge is to op-
timize glycaemic control with minimum number of medi-
cation while taking into consideration the cost of the ther-
apy, adverse eﬀect proﬁles, ease of administration, and the
urgency for blood sugar normalization.
Recent awareness of therapeutic potential of several tra-
ditionally used plants has opened a new dimension for
the study and research of medicinal plants. In traditional
medicine, several Indian medicinal plants or their extracts
have been used to treat diabetes [11].
Embelia ribes burm (family, Myrsinaceae) known com-
monly as vidanga is widely distributed throughout India. It
is highly esteemed in Ayurveda as a powerful anthelmintic
[12] and also an important ingredient of a number of
formulations [13, 14]. Ayurveda also describes vidanga as
pungent and cures ﬂatulence and colic. In a preliminary2 Experimental Diabetes Research
study, Tripathi [15] reported the antihyperglycemic activ-
ity of decoction of the E. ribes fruits in glucose-fed albino
rabbits. Further, Bhandari et al. [16] reported the poten-
tial of ethanolic extract of Embelia ribes in diabetic dys-
lipidemia and protection from lipid peroxidation in tis-




with ethanolic extract of E. ribes (100mg/kg and 200mg/kg)
on the basal level of some key serum and tissue antioxidants
was investigated in streptozotocin-induced oxidative damage
in rats.
2. MATERIAL AND METHODS
2.1. Preparationoftheextract
DriedE.ribesfruits,200g,werepurchasedlocallyfromagro-
cery shop in New Delhi (in India, it is commonly available)
and authenticated by Dr. M. P. Sharma, Taxonomist, Depart-
ment of Botany of our Institute. A voucher specimen was re-
tained in the department (UB# 04).
ThefruitswereSoxhletextractedwith90%ethanolfor72
hours. The solvent was removed under reduced pressure to
giveadriedextract,7.5%yieldw/w(withrespecttothecrude
material), and two doses equivalent to 100mg and 200mg
of the crude drug per kilogram body weight were calculated,




mittee (IAEC) (Registration no. and Date of Registration:
173/CPCSEA (Committee for the Purpose of Control and
SupervisionofExperimentsonAnimals),GovernmentofIn-
dia, dated 28th January, 2000).
Wistar rats of either sex (150 to 200g) were obtained
from the central animal house facility of Hamdard Univer-
sity, New Delhi. They were maintained under standard labo-
ratory conditions at 25 ± 2◦C, relative humidity (50 ± 15%)
and normal photoperiod (12-hour light-dark cycle) were
used for the experiment. Commercial pellet diet (MFD, by
Nav Maharastra Chakan Oil Mills Ltd., New Delhi, India)
and water were provided ad libitum.
After fasting 18 hours, the rats were injected intra-
venously through tail vein with a single dose of 40mg/kg
STZ (Sigma, St. Louis, Mo, USA), freshly dissolved in cit-
rate buﬀer (pH 4.5). After injection, the rats had free access
to food and water and were given 5% glucose solution to
drink overnight to counter hypoglycaemic shock. Diabetes
in rats were observed by moderate polydipsia and marked
polyuria.
After 3 days, the fasting blood glucose levels were deter-
minedbyorthotoluidinemethod[17].Theratsshowingfast-
ing blood glucose more than 200 mg/dL were considered di-
abetic and were selected for the experimentation [18].
2.3. Experimentaldesign
Normal and diabetic rats (n = 10 each) were randomly di-
v i d e di n t o5g r o u p so f1 0r a t se a c ha sf o l l o w s :
(I) group 1: control rats given 1mL of vehicle (1% tween
80) alone for 40 days;
(II) group 2: pathogenic diabetic rats (STZ treated only);
(III) group 3: STZ + ethanolic E. ribes extract treated
(100mg/kg);
(IV) group 4: STZ + ethanolic E. ribes extract treated
(200mg/kg);
(V) group 5: STZ + gliclazide treated (25mg/kg), a refer-
ence drug.
The test drug and reference standard drugs were fed
o r a l l yf o r4 0d a y s .G r o u p s1a n d2r a t sr e c e i v e d1 %t w e e n
80 solution orally once a day for 40 days.
The experiment was terminated at the end of 40 days and
the animals were fasted overnight.
2.4. Bloodcollectionandbiochemical
estimationsinserum
On 41st day, fasting blood samples were collected from the
tail vein of all the groups of rats. Whole blood was col-
lected for estimation of blood glucose [17], glycosylated
hemoglobin (HbA1C)[ 19], and glutathione [20] levels.
Serum was separated for estimation of speciﬁc serum
marker enzymes, namely, lactate dehydrogenase (LDH) [21,
22] and creatine kinase (CK) [23]. STZ-induced oxidative
stress in diabetes is also a predictor of cardiac damage. Since
LDH and CK are speciﬁc cardiac marker enzymes, increased
serum LDH and CK levels were considered as marker of ox-
idative stress-induced cardiac damage.
2.5. Biochemicalestimationinpancreatictissue
After blood collection, all the animals were sacriﬁced and
pancreas was dissected out. Tissue was washed with ice-
cold saline, weighed and minced; 10% homogenate was
prepared in 0.15M ice-cold KCl for TBARS (thiobarbi-
turic acid-reactive substances), a marker for lipid per-
oxidation [24] and protein estimation [25]; in 0.02M
EDTA for glutathione estimation [26]; and in phosphate
buﬀer (pH 7.4) for superoxide dismutase (SOD) [27]
and catalase estimations [28] using a Teﬂon tissue ho-
mogenizer. Decrease in levels of endogenous antioxidants
with rise in TBARS levels was considered as oxidative
stress.
2.6. Histologicalsectionofthepancreas
Pancreatic tissue was ﬁxed in 10% formalin, routinely pro-
cessed and embedded in paraﬃn wax. Paraﬃns e c t i o n s
(5μm) were cut on glass slides and stained with hematoxylin
and eosin (H and E) and were examined under a light micro-
scope by a pathologist blinded to the groups studied.Uma Bhandari et al. 3
Table 1: Eﬀect of ethanolic extract of Embelia ribes (ER) on whole blood glucose, whole blood glycosylated hemoglobin (HbA1c), blood






HbA1c(%) Blood GSH (mg/dL) Serum CK (IU/L) Serum LDH (IU/L)
I (Normal healthy control) 69.3 ±0.78 5.055 ±0.249 3.205 ± 0.074 60.74 ±3.1 191.11 ±7.40
II (STZ treated, i.e.,
pathogenic control) 344 ±11.34∗ 18.50 ±0.611∗ 1.115 ±0.077∗ 235.35 ±4.81∗ 477.17 ±34.86∗
III (STZ ± ER-100mg/kg) 104.7 ±1.84# 13.58 ±0.239# 2.69 ±0.2205# 183.13 ±7.9# 375.5 ± 23.92@
IV (STZ ± ER-200mg/kg) 87.7 ±1.84# 11.62 ±0.554# 4.147 ±0.225# 71.85 ±84# 273.84 ±26.47#
V( S T Z± gliclazide-25mg/kg) 79.05 ±1.261# 8.81 ±0.647# 2.082 ± 0.336 79.84 ± 4.42# 315.0 ±0.31#
∗P<. 01, as compared to group I (ANOVA followed by Dunnett’s t test).
#P<. 01, as compared to group II (ANOVA followed by Dunnett’s t test).
@P<. 05, as compared to group I (ANOVA followed by Dunnett’s t test).
Table 2: Eﬀect of ethanolic extract of Embelia ribes (ER) on lipid peroxides (TBARS), catalase (CAT), superoxide dismutase (SOD), and









GSH (μmol of phosphorus
liberated/min/mg protein)
I (Normal healthy control) 0.469 +0.046 3.92+ 0.075 4.80+ 0.089 56.26 + 2.860
II (STZ treated, i.e.,
pathogenic control) 6.802 + 0.895∗ 0.162 +0.030∗ 0.323 +0.010∗ 17.35 + 5.020
III (STZ ± ER-100mg/kg) 3.78 +0.833# 3.937 + 0.263# 2.767+ 0.770 34.20+ 3.500@
IV (STZ ± ER-200mg/kg) 0.488 +0.065# 2.236 + 0.066# 4.67+ 0.901# 39.20 + 1.070#
V( S T Z± gliclazide-25mg/kg) 2.159 +0.401# 3.62+ 0.475# 4.66+ 1.320# 46.1+2 .400#
∗P<. 01, as compared to group I (ANOVA followed by Dunnett’s t test).
#P<. 01, as compared to group II (ANOVA followed by Dunnett’s t test).
@P<. 05, as compared to group I (ANOVA followed by Dunnett’s t test).
2.7. Statisticalanalysis
Statistical analysis was carried out using GraphPad Prism
3.0 (GraphPad software: San Diego, Calif). All data were ex-
pressed as mean ± SEM. Groups of data were compared with
an analysis of variance followed by Dunnett’s t test. Values
were considered statistically signiﬁcant, when P<. 01.
3. RESULTS
Table 1 shows the levels of blood glucose and glycated
hemoglobin in normal and experimental rats. The levels of
glucose and glycated hemoglobin were elevated signiﬁcantly
in the group 2 diabetic control rats. After treatment with
ethanolic extract of E. ribes, the levels of glucose and glycated
hemoglobin were signiﬁcantly lowered in both doses. Fur-
ther, Table 1 shows the levels of serum marker antioxidant
enzymes (LDH, CK and glutathione). The levels of blood
glutathione in diabetic rats (group II) were signiﬁcantly low-
ered (P<. 01) when compared with those in normal control
rats of group 1. Treatment with ethanolic E. ribes (100mg/kg
and 200mg/kg) for 40 days signiﬁcantly restored the blood
GSHlevelsascomparedtogroupIIrats.Gliclazidetreatment
did not show any signiﬁcant increase in blood GSH levels
when compared to group 2.
Furthermore, the levels of other marker enzymes, that
is, LDH and CK were signiﬁcantly increased in group 2 di-
abetic rats. However, the test drug treatment for 40 days
signiﬁcantly reduced the levels of LDH (P<. 05 with
100mg/kg, i.e., group 3; P<. 01 with 200mg/kg, i.e., group
4) when compared to pathogenic diabetic rats.
Similarly, the administration of ethanolic extract of E.
ribes signiﬁcantly reduced (P<. 01) the serum CK levels in
both doses when compared to pathogenic diabetic control
rats and the results were comparable to gliclazide treatment
(group 5).
Table 2 presents the activities of the antioxidant en-
zymes in the pancreatic tissues in the control as well test
drug-treated animals. Signiﬁcant reduction in the activity
of SOD in pancreas of diabetic animals (group 2) was
observed in comparison to normal rats, that is, group 1.
Diabetic rats treated with ethanolic extract of E. ribes
(100mg/kg and 200mg/kg) showed normal enzymatic
activity.4 Experimental Diabetes Research
Catalase activity was signiﬁcantly (P<. 01) decreased in
diabetic animals as compared to normal control rats, that is,
group 1. The levels were signiﬁcantly (P<. 01) increased
with ethanolic extract of E. ribes (in a dose of 200mg/kg).
Total glutathione activity was reduced by 69.13% in pan-
creatic tissue of diabetic rats as compared to normal con-
trol animals. The levels were signiﬁcantly (P<. 01) in-
creased with ethanolic extract of Embelia ribes (in a dose of
200mg/kg).
3.1. Histopathologicalexamination
Figures 1–5 depict the islet cells of the pancreas of rat in dif-
ferent groups. Figure 1 shows globules of acini with normal
islet cells. The atrophy of islets cells with inﬂammatory inﬁl-
t r a t ew i t he d e m aw a so b s e r v e di ng r o u p2d i a b e t i cr a t sw h e n
compared to group 1 control rats. Treatment of diabetic rats
withthetestdrugingroup3showedisletcellswithcongested
acinis. However, group 4 treatment showed normal pancre-
atic cells, and gliclazide treatment in group 5 showed moder-
ate expansion of islets cells.
4. DISCUSSION
The islet β-cells are susceptible to damage caused by oxygen-
free radicals [29] since the antioxidant defense system is
weak under diabetic condition [30] .T h el e v e l so fa n t i o x -
idant defense system are altered in STZ-induced diabetic
rats, which is in good correlation with the present obser-
vation [31]. Nonprotein thiols like glutathione are one of
the important primary defenses that counteract the oxida-
tive stress. We observed lower levels of serum glutathione in
STZ diabetic rats, which is in consistent with earlier reports
[31, 32] .T h eo b s e r v e dd e c r e a s em a yb ed u et ou t i l i z a t i o n
of nonprotein thiols by increased oxygen-free radicals pro-
duced in hyperglycemic conditions associated with diabetes
mellitus.
Increased serum CPK and LDH levels in diabetic rats in-
dicate cardiac muscular damage [33]. Similar increase in the
activity of these two enzymes in serum of the STZ diabetic
rats was observed in the present study. The quantity of en-
zyme released from the damaged tissue is a measure of the
number of necrotic cells [34].
Further, STZ-treatment in animals decreased the ac-
tivity of marker enzymes in pancreatic tissue. SOD is an
important defense enzyme which catalyzes the dismutation
of superoxide radicals [35]. Catalase is a hemoprotein which
catalyzes the reduction of hydrogen peroxides and protects
thetissuesfromhighlyreactivehydroxylradicals[36].There-
fore, reduction in the activity of these enzymes (SOD, CAT)
results in a number of deleterious eﬀects due to the accu-
mulation of superoxide anion radicals and hydrogen perox-
ides.Lipidperoxidationisoneofthecharacteristicfeaturesof
chronicdiabetes[37].Inthepresentstudy,amarkedincrease
in the concentration of TBARS was observed in the pancre-
atic tissue of diabetic rats. Higher levels of lipid peroxides
and low SOD and CAT activity indicate an oxidative stress
condition.
Figure 1: Typical photomicrograph of the pancreas of normal con-
t r o lr a t s( g r o u p1 ) ,Ha n dE× 10 shows normal islets.
Figure 2: Typical photomicrograph of the pancreas of pathogenic
diabetic (STZ only) control rats (group 2), H and E × 10 shows
shrunken islets.
Figure 3: Typical photomicrograph of the pancreas of STZ + Em-
belia ribes (100mg/kg) treated rats (group 3), H and E × 10 shows
congested acinis.
Figure 4: Typical photomicrograph of the pancreas of STZ + Em-
belia ribes (200mg/kg) treated rats (group 4), H and E × 10 shows
normal pancreatic islets.Uma Bhandari et al. 5
Figure 5: Typical photomicrograph of the pancreas of STZ +
gliclazide-treated rats (group 5), H and E × 10 shows moderate ex-
pansion of islets.
TheethanolicextractofEmbelia ribes producedamarked
decrease in blood glucose levels at 100mg/kg and 200mg/kg
bodyweightinSTZ-diabeticratsafter40daystreatment.The
antidiabetic eﬀect of Embelia ribes may be due to increased
release of insulin from the existing β-cells of pancreas similar
to that observed after gliclazide administration.
Treatment of diabetic rats with the ethanolic extract of
Embelia ribes signiﬁcantly increased the levels of nonprotein
thiols in serum as well as in pancreatic tissues of rats as com-
pared to pathogenic diabetic rats. It has been reported by
Sreepriya and Bali [38] while studying liver cancer protect-
ing eﬀect of Embelin, a constituent of Embelia ribes in rats,
that Embelin signiﬁcantly scavenges free radicals; and re-
sulting in hepatic glutathione antioxidant defense decreases
lipid peroxidation and minimizes the histological (liver) al-
terationsinducedbyN-nitrosodiethylamine(200mg/kg,sin-
gle intraperitoneal (IP) injection) and phenobarbital (0.05%
in drinking water) fed orally for 13 weeks [38]. In our study,
we also observed signiﬁcant (P<. 01) increase in levels of
blood glutathione, as well as pancreatic levels of glutathione
in diabetic rats when treated with ethanolic extracts of Em-
belia ribes. Further, the activities of SOD and CAT were also
increased in the pancreatic tissues of test drug-treated dia-
betic animals. The antioxidant activity of the test drug might
have been due to the inhibition of glycation of the antioxi-
dant enzymes SOD and CAT. Glucose which forms Schiﬀ’s
base with proteins has been reported to have high aﬃnity
for proteins especially those containing transition metal ions
[39].IncreasedglycatedCu-Zn-SODhasbeenreportedindi-
abetes. A study on curcumin (active principle of rhizome of
Curcuma longa) has shown that curcumin inhibits advanced
glycation end products in STZ diabetes in rats [40]. In the
present study too, we observed a decrease in the glycated
hemoglobin in rats treated with the ethanolic extract of Em-
belia ribes which is not reported earlier. Since the level of gly-
cosylated hemoglobin has been shown to provide an index of
blood glucose concentration during the previous 1-2-month
period, it is being used increasingly in the clinical manage-
ment of diabetes [41].
Furthermore, there was a signiﬁcant attenuation of
serum LDH and creatine kinase levels with the test drug
treatment indicating the cardioprotective eﬀect of ethanolic
extract of Embelia ribes.
In the Embelia ribes 200mg/kg dose, signiﬁcant protec-
tion against STZ-induced oxidative stress was observed. The
treatment showed normal pancreatic β-cells (Figure 4). The
protection might have been mediated through an Embelia
ribes-induced increase in basal pancreatic SOD and catalase
activities.
Hence, we conclude that the ethanolic extract of Embe-
lia ribes oﬀers protection of β-cells against reactive oxygen
species-mediated damage by enhancing cellular antioxidant
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